1DOUILLARD J v, SHEPHERD F A, HIRSH V, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small- cell lung cancer: date from the randomized phase III IN TERES T trial[J].J Clin Oncol, 2010, 28(S):744-752.
2CAPPUZZO F, CIULEANU T, STELMAKH L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studv[J]. Lancet Oneal, 2010,11(6):521-529.
3RHO J K, CHOI Y J, JEON B S, et al. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation[J]. Mal Cancer Ther, 2010, 9(12):3233-3243.
4MA C, WEI S, SONG Y. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports[J]. Tharacic Dis, 2011, 3(1): 10-18.
5EBERHARD D A, JOHNSON B Eo AMLER L C, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J].J Clin Oncol, 2005, 23(25): 5900-5909.
6JACKMAN D, PAO W, RIELY G J, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J].J Clin Oneal, 2010,28(2):357-360.
7LI D, AMBROGIO L, SHIMAMURA T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models[J], Oncogene, 2008, 27(34):4702-4711.
8REGLES L, GONG Y, SHEN R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of ECFR mutant lung cancer[J].J Clin Invest, 2009, 119(10):3000-3010.
9MOK T S, WU Y L. THONGPRASERT S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361 :947-957.
10ENGELMAM J A, ZEJNULLAHU K, MITUDOMI T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling[J]. Science, 2007, 316(5827):1039-1043.
